Hilde Azijn

2.9k citations

20 papers · 2.4k indexed · h-index 16

Co-authors: Marie‐Pierre de Béthune Rudi Pauwels Johan Vingerhoets Dirk Jochmans Koen Andries Gastón Picchio Sandra De Meyer Dominique Surleraux
Topics: HIV Research and Treatment (18 papers)HIV/AIDS drug development and treatment (18 papers)HIV/AIDS Research and Interventions (10 papers)
Cited by: Virology Infectious Diseases Hepatology
Journals: Journal of Virology Journal of Medicinal Chemistry Antimicrobial Agents and Chemotherapy
Partner nations: United States Belgium United Kingdom

In The Last Decade

Hilde Azijn

20 papers receiving 2.2k citations

Peers

Countries citing papers authored by Hilde Azijn

Since Specialization

Citations

This map shows the geographic impact of Hilde Azijn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hilde Azijn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hilde Azijn more than expected).

Fields of papers citing papers by Hilde Azijn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hilde Azijn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hilde Azijn. The network helps show where Hilde Azijn may publish in the future.

Co-authorship network of co-authors of Hilde Azijn

This figure shows the co-authorship network connecting the top 25 collaborators of Hilde Azijn. A scholar is included among the top collaborators of Hilde Azijn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hilde Azijn. Hilde Azijn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Connection Domain Mutations in HIV-1 Reverse Transcriptase Do Not Impact Etravirine Susceptibility and Virologic Responses to Etravirine-Containing Regimens 2011 ·Antimicrobial Agents and Chemotherapy ·Soumi Gupta,Johan Vingerhoets,Signe Fransen,Lotke Tambuyzer,Hilde Azijn,(unknown),Roger Paredes,Eoin Coakley,Steven Nijs,Bonaventura Clotet,Christos J. Petropoulos,Jonathan Schapiro,Wei Huang,Gastón Picchio	27
2	Characterization of Genotypic and Phenotypic Changes in HIV-1-Infected Patients with Virologic Failure on an Etravirine-Containing Regimen in the DUET-1 and DUET-2 Clinical Studies 2010 ·AIDS Research and Human Retroviruses ·Lotke Tambuyzer,Johan Vingerhoets,Hilde Azijn,(unknown),Steven Nijs,Marie‐Pierre de Béthune,Gastón Picchio	45
3	Short Communication: Activity of Etravirine on Different HIV Type 1 Subtypes: In Vitro Susceptibility in Treatment-Naive Patients and Week 48 Pooled DUET Study Data 2010 ·AIDS Research and Human Retroviruses ·Johan Vingerhoets,Hilde Azijn,Lotke Tambuyzer,Inge Dierynck,Sandra De Meyer,L Rimsky,Steven Nijs,Goedele De Smedt,Marie‐Pierre de Béthune,Gastón Picchio	11
4	Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies 2010 ·AIDS ·Johan Vingerhoets,Lotke Tambuyzer,Hilde Azijn,Annemie Hoogstoel,Steven Nijs,Monika Peeters,Marie‐Pierre de Béthune,Goedele De Smedt,Brian Woodfall,Gastón Picchio	137
5	Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials 2010 ·AIDS ·Monika Peeters,Johan Vingerhoets,Lotke Tambuyzer,Hilde Azijn,Andrew Hill,Sandra De Meyer,Gastón Picchio	12
6	Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors 2009 ·Antiviral Therapy ·Lotke Tambuyzer,Hilde Azijn,L Rimsky,Johan Vingerhoets,Pierre Lecocq,Guenter Kraus,Gastón Picchio,Marie‐Pierre de Béthune	75
7	TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1 2009 ·Antimicrobial Agents and Chemotherapy ·Hilde Azijn,(unknown),Johan Vingerhoets,Marie‐Pierre de Béthune,Guenter Kraus,Katia Boven,Dirk Jochmans,Elke Van Craenenbroeck,Gastón Picchio,L Rimsky	246
8	Etravirine protects the activity of darunavir in the DUET trials 2008 ·Journal of the International AIDS Society ·Marc Peeters,Johan Vingerhoets,Lotke Tambuyzer,Hilde Azijn,(unknown),Sandra De Meyer,Gastón Picchio	2
9	Inhibition of Human Immunodeficiency Virus Type 1 Infection by the Candidate Microbicide Dapivirine, a Nonnucleoside Reverse Transcriptase Inhibitor 2008 ·Antimicrobial Agents and Chemotherapy ·Patricia Fletcher,(unknown),Hilde Azijn,(unknown),(unknown),(unknown),(unknown),Jeremy Nuttall,Joseph Romano,Robin J. Shattock	93
10	Design of HIV-1 Protease Inhibitors Active on Multidrug-Resistant Virus 2005 ·Journal of Medicinal Chemistry ·Dominique Surleraux,(unknown),(unknown),Geert Pille,Louis Maes,Anik Peeters,Sandrine Vendeville,Sandra De Meyer,Hilde Azijn,Rudi Pauwels,Marie‐Pierre de Béthune,Nancy M. P. King,M. Prabu-Jeyabalan,Celia A. Schiffer,Piet Wigerinck	59
11	TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates 2005 ·Antimicrobial Agents and Chemotherapy ·Sandra De Meyer,Hilde Azijn,Dominique Surleraux,Dirk Jochmans,Abdellah Tahri,Rudi Pauwels,Piet Wigerinck,Marie‐Pierre de Béthune	294
12	TMC125 Displays a High Genetic Barrier to the Development of Resistance: Evidence from In Vitro Selection Experiments 2005 ·Journal of Virology ·Johan Vingerhoets,Hilde Azijn,Els Fransen,(unknown),(unknown),Dirk Jochmans,Koen Andries,Rudi Pauwels,Marie‐Pierre de Béthune	205
13	Design, Synthesis, and SAR of a Novel Pyrazinone Series with Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitory Activity 2004 ·Journal of Medicinal Chemistry ·Jan Heeres,Marc R. de Jonge,Lucien M. H. Koymans,Frits Daeyaert,Maarten Vinkers,Koen Van Aken,Eddy Arnold,Kalyan Das,(unknown),Georges J. Hoornaert,Frans Compernolle,Marek Cegła,Rasha A. Azzam,Koen Andries,Marie‐Pierre de Béthune,Hilde Azijn,Rudi Pauwels,Paul Lewi,Paul A. J. Janssen	45
14	TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1 2004 ·Antimicrobial Agents and Chemotherapy ·Koen Andries,Hilde Azijn,(unknown),Donald Ludovici,Michael J. Kukla,Jan Heeres,Paul Janssen,Bart De Corte,Johan Vingerhoets,Rudi Pauwels,Marie‐Pierre de Béthune	265
15	Discovery and Selection of TMC114, a Next Generation HIV-1 Protease Inhibitor 2004 ·Journal of Medicinal Chemistry ·Dominique Surleraux,Abdellah Tahri,(unknown),Geert Pille,(unknown),Tim H. M. Jonckers,Anik Peeters,Sandra De Meyer,Hilde Azijn,Rudi Pauwels,Marie‐Pierre de Béthune,Nancy M. P. King,M. Prabu-Jeyabalan,Celia A. Schiffer,Piet Wigerinck	199
16	Evolution of Anti-HIV Drug CandidatesPart 2: Diaryltriazine (DATA) Analogues 2001 ·Bioorganic & Medicinal Chemistry Letters ·Donald Ludovici,Robert W. Kavash,Michael J. Kukla,Chih Y. Ho,Hong Ye,(unknown),Koen Andries,Marie‐Pierre de Béthune,Hilde Azijn,Rudi Pauwels,(unknown),Jan Heeres,Lucien M. H. Koymans,Marc R. de Jonge,Koen Van Aken,(unknown),Paul Lewi,Kalyan Das,Eddy Arnold,Paul A. J. Janssen	98
17	Evolution of anti-HIV drug candidates. Part 1: From α-Anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU) 2001 ·Bioorganic & Medicinal Chemistry Letters ·Donald Ludovici,Michael J. Kukla,(unknown),Suma Krishnan,Koen Andries,(unknown),Hilde Azijn,Rudi Pauwels,Erik De Clercq,Eddy Arnold,(unknown)	62
18	Evolution of anti-HIV drug candidates. Part 3: diarylpyrimidine (DAPY) analogues 2001 ·Bioorganic & Medicinal Chemistry Letters ·Donald Ludovici,(unknown),Michael J. Kukla,Hong Ye,Chih Y. Ho,(unknown),Robert W. Kavash,Koen Andries,(unknown),Hilde Azijn,Rudi Pauwels,Paul Lewi,Jan Heeres,Lucien M. H. Koymans,Marc R. de Jonge,Koen Van Aken,(unknown),Kalyan Das,Eddy Arnold,Paul A. J. Janssen	154
19	A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of Protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs 1998 ·Antimicrobial Agents and Chemotherapy ·Kurt Hertogs,Marie‐Pierre de Béthune,Veronica Miller,Tania Ivens,(unknown),(unknown),Christel Van den Eynde,(unknown),Hilde Azijn,Margriet Van Houtte,(unknown),Schlomo Staszewski,Marcus A. Conant,Stuart Bloor,Sharon D. Kemp,Brendan Larder,Rudi Pauwels	338
20	Automated techniques in biotechnology 1995 ·Current Opinion in Biotechnology ·Rudi Pauwels,Hilde Azijn,Marie‐Pierre de Béthune,Carine Claeys,Kurt Hertogs	3

About Hilde Azijn

Hilde Azijn is a scholar working on Virology, Infectious Diseases and Hepatology, having authored 20 papers that have together received 2.4k indexed citations. Recurring topics across this work include HIV Research and Treatment (18 papers), HIV/AIDS drug development and treatment (18 papers) and HIV/AIDS Research and Interventions (10 papers). The work is most often cited by research in Virology (1.9k citations), Infectious Diseases (2.1k citations) and Hepatology (160 citations). Hilde Azijn has collaborated with scholars based in United States, Belgium and United Kingdom. Frequent co-authors include Marie‐Pierre de Béthune, Rudi Pauwels, Johan Vingerhoets, Dirk Jochmans, Koen Andries, Gastón Picchio, Sandra De Meyer, Dominique Surleraux, Piet Wigerinck and Abdellah Tahri. Their work appears in journals such as Journal of Virology, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact